Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 10,564 matching trials from the live ClinicalTrials.gov search.

Filters: Cincinnati, Ohio Clear all

Conditions: Anterior Cruciate Ligament Injuries
Interventions: aNMT Biofeedback, Sham Biofeedback; Other
Lead sponsor: Emory University; Other
Eligibility: 12 Years to 19 Years · Female only
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Flowery Branch, Georgia • Cincinnati, Ohio

Conditions: COVID-19
Interventions: BRII-196, BRII-198, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 76
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 150 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 25
States / cities: Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more

Conditions: Asthma
Interventions: Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Breast Cancer
Interventions: Letrozole, Anastrozole; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 33 Years to 96 Years · Female only
Enrollment: 4,172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 42
States / cities: Birmingham, Alabama • Huntsville, Alabama • Flagstaff, Arizona + 35 more

Conditions: Hereditary Angioedema (HAE)
Interventions: C1 esterase inhibitor [human] liquid, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more

Conditions: Hypertension
Interventions: Aliskiren; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 43
States / cities: Los Angeles, California • Riverside, California • Santa Monica, California + 38 more

Conditions: Prostate Cancer
Interventions: bicalutamide, estramustine, etoposide, flutamide, goserelin, leuprolide, nilutamide, paclitaxel; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 91
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more

Conditions: Urinary Bladder, Overactive
Interventions: solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 441 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 104
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 90 more

Conditions: Hemolytic Disease of the Fetus and Newborn
Interventions: M281; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 8
States / cities: San Francisco, California • New York, New York • Cincinnati, Ohio + 5 more

Conditions: Ruptured Cerebral Aneurysm, Ruptured Berry Aneurysm
Interventions: Nimodipine, Nimodipine Microparticles; Drug
Lead sponsor: Edge Therapeutics Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 11 more

Conditions: Hypoplastic Left Heart Syndrome
Interventions: Lomecel-B medicinal signaling cells; Biological
Lead sponsor: Longeveron Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 6 more

Conditions: Papilloma Viral Infection
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 9 Years to 17 Years · Female only
Enrollment: 1,321 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Tucker, Georgia • Baltimore, Maryland • Kansas City, Missouri + 4 more

Conditions: Single Ventricle Heart Disease After Fontan Surgery
Interventions: Udenafil; Drug
Lead sponsor: Mezzion Pharma Co. Ltd; Industry
Eligibility: 14 Years to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Cincinnati, Ohio + 2 more

Conditions: Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
Interventions: Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 15
States / cities: Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more

Conditions: HIV Infections, Pregnancy
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 60 Years
Enrollment: 1,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more

Conditions: Focus: Assess Post Infusion Viability of S303 RBCs
Interventions: S303 Red Blood Cells (RBCs), Conventional, untreated Red Blood Cells (RBCs); Biological
Lead sponsor: Cerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Cincinnati, Ohio • Milwaukee, Wisconsin

Conditions: Dyslipidemia
Interventions: Placebo, Pravastatin, Dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 33
States / cities: Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more

Conditions: Asthma
Interventions: ELLIPTA DPI, GSK MDI, AZ MDI; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: Diaper Dermatitis
Interventions: Air Therapy; Other
Lead sponsor: TriHealth Inc.; Other
Eligibility: 30 Weeks to 1 Year
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: Vandetanib, Pemetrexed; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 23
States / cities: Casa Grande, Arizona • Chandler, Arizona • Farmington, Connecticut + 20 more

Conditions: Neuroblastoma
Interventions: Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan, Dinutuximab, GM-CSF; Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 31 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Postmenopausal Osteoporosis
Interventions: Not listed
Lead sponsor: Warner Chilcott; Industry
Eligibility: Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more

Search by objective public record fields.

Neuroplastic Mechanisms Underlying Augmented Neuromuscular Training

BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer

Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.

Immunogenicity of Off-Schedule Dosing of HPV Vaccine

Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Neonatal Intensive Care Unit (NICU) Diaper Dermatitis: Prevention and Treatment With Airtime

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate